We revealed that either cardiomyocyte-specific YOD1 knockout (YOD1CKO) or pharmacological inhibition of YOD1 significantly attenuates Ang II–induced cardiac hypertrophy and dysfunction in mice. This evidence concerns the gene AGT and cardiac hypertrophy.